Home/Pipeline/IgG Next Generation / Yimmugo (BT595)

IgG Next Generation / Yimmugo (BT595)

Primary Immune Deficiency (PID)

ApprovalActive

Key Facts

Indication
Primary Immune Deficiency (PID)
Phase
Approval
Status
Active
Company

About Biotest Pharmaceuticals

Biotest Pharmaceuticals is a long-established, revenue-generating commercial biopharma company focused on plasma-derived biologics. It maintains a vertically integrated model, controlling plasma collection through its own network of centers. The company has a commercial portfolio for immunology, haematology, and intensive care, and is advancing a late-stage pipeline including next-generation immunoglobulins and novel therapies like Trimodulin for severe pneumonia.

View full company profile

About Biotest Pharmaceuticals

Biotest Pharmaceuticals is a long-established, revenue-generating commercial biopharma company focused on plasma-derived biologics. It maintains a vertically integrated model, controlling plasma collection through its own network of centers. The company has a commercial portfolio for immunology, haematology, and intensive care, and is advancing a late-stage pipeline including next-generation immunoglobulins and novel therapies like Trimodulin for severe pneumonia.

View full company profile